Potential Genotoxic Impurity (PGI) Assessment

In the modern pharmaceutical landscape, the pursuit of drug efficacy is always matched by an unyielding commitment to patient safety. As we navigate the complexities of drug development, one area has increasingly demanded precision, rigor, and regulatory expertise: the identification and control of potential genotoxic impurities (PGIs). At our company, we specialize in providing end-to-end PGI assessment services, ensuring that your pipeline remains robust, compliant, and—above all—safe for human health.

Understanding Potential Genotoxic Impurities

PGIs are substances that, even at very low concentrations, have the potential to damage DNA, causing mutations that may lead to cancer. Because these impurities can arise at various stages of the manufacturing process, from starting materials and reagents to intermediates and by-products, their presence must be strictly controlled. Therefore, regulatory frameworks such as ICH M7 guidelines require thorough assessment and control strategies to limit patient exposure. The challenge for pharmaceutical developers lies in balancing the rigorous need for detection with the efficiency of the drug development timeline. Failing to identify a PGI early can result in costly project delays, clinical holds, or regulatory rejection.

Our Holistic Assessment Workflow

Our service is built upon a tiered approach that aligns with international regulatory standards. We do not merely "test for impurities"; we provide a comprehensive risk management strategy.

Mitigation and Control Strategies

Identifying a PGI is only the first step. The true value of our service lies in our ability to provide actionable solutions for mitigation. If a PGI is confirmed, we work closely with your process chemistry teams to:

• Process Optimization: Adjust reaction conditions, solvents, or purification steps to minimize or eliminate the formation of the impurity at the source.
• Purification Strategy: Design robust downstream processes (e.g., crystallization, chromatography) to ensure the PGI is purged effectively.
• Justification of Thresholds: If the PGI cannot be eliminated, we assist in preparing the toxicological justification for higher limits, adhering to the "Carcinogenic Potency Categorization Approach" where applicable.

Why Partner with Us?

• Regulatory Track Record: Our reports are designed to be "inspection-ready." We have a deep understanding of what global health authorities, such as the FDA, EMA, and NMPA, look for in PGI assessment dossiers.
• Scientific Expertise: Our multidisciplinary team includes toxicologists, analytical chemists, and regulatory specialists with extensive experience in genotoxicity assessment.
• Advanced Technology: We utilize cutting-edge computational tools and analytical platforms to deliver accurate and reliable results.
• Speed and Efficiency: We understand that every day counts in the drug development race. Our streamlined process, from in silico screening to validated analytical testing, is designed to minimize timelines without compromising scientific integrity.

Please kindly note that our services are for research use only.